Pharma

News round-up by DDW’s Megan Thomas for 19 – 23 July DDW’s Megan Thomas rounds up her top five stories this week which facilitate the continuation of vital drug discovery research, from partnerships and funding to successful trials and informative reports. Exscientia accelerates Covid-19 drug discovery using AI Exscientia has received a grant from the […]

Botanical Holdings was founded in early 2020 with a focus on investing within the legal cannabis sector. There is now a substantial body of evidence to support the effectiveness of cannabis-based medicines in treating a range of conditions from epilepsy to chronic pain. More recently, attention has also turned to the potential of certain psychedelic […]

New research reveals that 50% of European and US pharmaceutical manufacturing companies know artificial intelligence (AI) can help bring new drugs to market more rapidly and securely, but 96% face challenges with using it to derive value from their data. 49% of all executives surveyed say their company has no overarching strategy for while 31% […]

At an update to investors, GlaxoSmithKline (GSK) provided details of its strategy, outlook for growth and plans to create shareholder value, following the planned demerger in mid-2022 of its Consumer Healthcare business. An equity research expert suggests that while targets are friendly, investors will not get a completely clean break from the new consumer business. […]

News round-up by DDW’s Megan Thomas for 5 – 9 July We know that innovation is key in the drug discovery and development sector. DDW’s Megan Thomas rounds up her top five stories this week which highlight the industry’s on-going work to create breakthrough therapeutics for global wellbeing. New approach will help identify drugs that […]

Last month, the AI-driven pharma-tech company, Exscientia announced that the world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) was entering Phase I clinical trials. This is the result of a collaboration with DSP, a Japanese pharmaceutical company. The drug candidate is being assessed for antipsychotic effects associated with AD psychosis, as […]

Marilyn Matz, CEO of Paradigm4, and Zachary Pitluk, Vice President of Life Sciences at Paradigm4, explain why scalable data science platforms are key to supporting integrated analysis of single-cell genomic data sets.  As researchers approach the practical limits of flow cytometry and are challenged to simultaneously explore the thousands of proteins expressed by the genome […]

Optibrium has published a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”, working alongside Takeda Pharmaceuticals’ proprietary global dataset and the Alchemite deep learning method. The study demonstrated that deep learning generates new and valuable insights on global pharma-scale, high-value and proprietary datasets. Such datasets are complex, with data deriving […]

Ahead of the return of CPhI North America, Informa Markets has commissioned an in-depth report into the US pharma market focusing on how the pandemic has affected public discourse and political priorities, and how it could alter the pharmaceutical supply paradigm in the medium term. Analysis from six leading US experts – following extensive interviews […]

Chinese biopharma companies are eyeing strategic collaborations with Western counterparts to leverage their networks and commercial capabilities to promote indigenously developed drugs in China, says GlobalData, a data and analytics company. China-based Luye Pharma Group’s holding subsidiary Boan Biotech signed an agreement with AstraZeneca China in May 2021 regarding the promotion rights to the anticancer […]

Aly King-Smith is Director of Clearworks, based at the historic Caswell Science Park in Northamptonshire. King-Smith speaks with DDW’s Megan Thomas about Clearworks’ Lab To Leadership initiative, established to inspire leaders in STEM. MT: Could you provide a general overview of the course and the company behind it? AKS: Lab To Leadership is a specialist […]

Increasingly, pharma companies are looking for a one-stop-shop when outsourcing clinical research support. Outsourcing without focusing on safety, however, is turning out to be a costly decision for some companies, leading to mistakes and budget overrun. Natalia Vlcek, Pharmacovigilance Manager and EU QPPV at Arriello Group, contends that it is time that safety became a […]

With the latest EU IDMP guidance now published, pharma companies must now measure their readiness for the new world, in which data-based regulatory submissions run parallel with, and will ultimately replace, single-use documents. Here, Adnan Jamil, a Senior Consultant at data-driven life sciences transformation specialist, Iperion, offers step-by-step advice to pharma companies keen to reap […]

Biopharmaceutical innovator Sanofi has launched a €3 million Planet Mobilisation fund to support employee ideas and projects that will further contribute to a healthier environment. In 2021, three Sanofi teams will have their projects implemented and funded. For several years, Sanofi has been implementing a global environmental roadmap, Planet Mobilisation, which is embedded in Sanofi’s […]

4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn Quigley, Head of Gastroenterology and […]

By Mette Lauritzen PhD, Product Marketing Manager, Nuclear Molecular Imaging, Bruker BioSpin Different types of tumours, and their varying reactions to treatment, make the search for new effective cancer therapies incredibly challenging. Preclinical in vivo imaging methods are helping to obtain further knowledge of tumour morphology, progression, and biomarker expression by enabling the visualisation of […]